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HPV16 is the most carcinogenic HPV type, but only a minority of HPV16 infections progress to cancer.
Intratype genetic variants of HPV16 have been suggested to confer differential carcinogenicity. To
investigate risk implications of HPV16 variants among Chinese women, a case-control study was con-
ducted with 298 cervical cancer patients and 85 controls (all HPV16-positive). HPV16 isolates were
predominantly of the A variant lineage, and variants of A4 (previously named “Asian”) sublineage were
common. A4/Asian variants were signiﬁcantly associated with increased risk of cervical cancer compared
to A1–3 (OR¼1.72, 95% CI¼1.04–2.85). Furthermore, a meta-analysis including 703 cases and 323
controls from East Asia conﬁrmed the association (OR¼2.82, 95% CI¼1.44–5.52). In conclusion, A4
variants appear to predict higher risk of cervical cancer among HPV16-positive women, which may
provide clues to the genetic basis of differences in the carcinogenicity of HPV16 variants.
& 2015 Elsevier Inc. All rights reserved.Introduction
Cervical cancer ranks as the fourth most common malignancy
in females worldwide, with a relatively high burden in developing
countries, including in China (Ferlay et al., 2015). Infection with a
subset of human papillomavirus (HPV), termed high-risk types, is a
necessary pre-requisite for this disease (zur Hausen, 2002). Nota-
bly, although approximate 80% of women will have acquired cer-
vical HPV infection by age 50, less than 1% of persistent infections
will ultimately lead to invasive cancer (Myers et al., 2000; Schiff-
man et al., 2011). Factors that inﬂuence the outcome of HPV
infection are not fully understood, but HPV intratype variants have
been suggested to play a critical role in cervical carcinogenesis,
and are recognized as an important marker for research on viral
transmission, persistence, and carcinogenicity (Wang and Hilde-
sheim, 2003; Xi et al., 2014).r Prevention and Control,
edical Sciences, No. 17 Pan-
ina. Tel.: þ86 10 8778 7394;
.Of the 13 key genital high-risk human papillomavirus types
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), HPV16 is
the most prevalent type, and causes more than half of cervical
cancer cases worldwide (Guan et al., 2012). Based on whole HPV
genome sequencing, HPV16 variants have been classiﬁed into four
major lineages: (1) A, that includes A1–3 (previously named Eur-
opean), and A4 (Asian) sublineages; (2) B (African 1); (3) C (African
2); and (4) D (including Asian–American [AA] and North-American
[NA]) (Burk et al., 2013).
Epidemiological studies have suggested that certain HPV16
variants, particular D lineages, might promote viral persistent
infection and cervical cancer development (Berumen et al., 2001;
Schiffman et al., 2010; Xi et al., 2007). However, D lineages are rare
in East Asia, where A lineages predominate (Cornet et al., 2013;
Yamada et al., 1997). In particular, the prevalence in cervical cancer
of A4/Asian variants (most commonly classiﬁed by the poly-
morphism T178G in E6) is much higher in Asia (65.5% in China,
85.2% in Korea, and 44% in Japan) than in Europe (2%) and North
America (3%) (Kang et al., 2005; Matsumoto et al., 2000; Wu et al.,
2006; Yamada et al., 1997). However, in comparison to a number of
relevant studies in European and American populations, little is
known about the oncogenic potential of HPV16 variants in Asian
women. A4/Asian variants were associated with a higher risk of
Table 1
Nucleotide polymorphisms identiﬁed at HPV16 E6 gene.
Varianta 94 109 111 131 132 136 145 154 168 173 176 178 184 188 193 219 241 267 276 286 295 310 315 335 350 442 516 Predicted amino
acid change
Case
(N¼298)
Control
(N¼85)
Total
HPV16
reference
G T A A G G G A C C G T A G T G T G A T T T C C T A C
A1–3 – – – – – – – – – – – – – – – – – – – – – – – – – – – – 98 35 133
a – – – – – – – – – – – – – – – – – – – – – – – – – – – 12 6 18
a – – – – – – – – – A – – – – – – – – – – – – – – – – D25N 1 2 3
a – – – – – – – – – A – – – – – – – – – – – – – G – – D25N/L83V 1 0 1
a – – – – – – – – – – A – – – – – – – – – – – – – – – D25E 10 1 11
a – – – – – – – – – – A – – – – – – – – – – – T – – – D25E/H78Y 1 0 1
a – – – – – – – – – – – – – – – – – – – – – G – – – – S71C 1 0 1
a – – – – – – – – – – – – – – – – – – – – – – T – – – H78Y 1 2 3
a – – – – – – – – – – – – – – – – – – – – – – – G – – L83V 0 1 1
– c – – – – – – – – – – – – – – – – – – – – – – G – – L83V 0 1 1
– – – – – T – – – – – – – – – – – – – – – – – – – – – K11N 1 0 1
– – – – – – – G G – – – – – – – – – – – – – – – G – – T22S/L83V 1 0 1
– – – – – – – – – T C – – C – – – – – – – – – – – – – H24Y/D25H/E29Q 1 0 1
– – – – – – – – – – A – – – – – – – – – – – – – – – – D25N 9 0 9
– – – – – – – – – – C – – – – – – – – – – – – – – – – D25H 1 0 1
– – – – – – – – – – T – – – – – – – – – – – – – – – – D25Y 1 0 1
– – – – – – – – – – A – – – – – g – – – – – – – – – – D25N 1 0 1
– – – – – – – – – – – – G – – – – – – – – – – – – – – I27M 0 1 1
– – – – – – – – – – – – – C – – – – – – – – – – – – – E29Q 1 0 1
– – – – – – – – – – – – – – – A – – – – – – – – – – – R39Q 1 0 1
– – – – – – – – – – – – – – – – g – – – – – – – – – – – 7 4 11
– – – – – – – – – – – – – – – – – – G – – – – – – – – N58S 1 2 2
– – – – – – – – – – – – – – – – – – – – G – – – – – – D64E 1 0 1
– – – – – – – – – – – – – – – – – – – – G – – – G – – D64E/L83V 2 1 3
– – – – – – – – – – – – – – – – – – – – – G – – – – – F69L 1 0 1
– – – – – – – – – – – – – – – – – – – – – – – T G – – H78Y/L83V 1 0 1
– – – – – – – – – – – – – – – – – – – – – – – T – C – H78Y/E113D 1 0 1
– – – – – – – – – – – – – – – – – – – – – – – – G – – L83V 3 1 4
– – – – – – – – – – – – – – – – – – – – – – – – G C – L83V/E113D 1 0 1
– – – – – – – – – – – – – – – – – – – – – – – – G – G L83V/S138C 0 1 1
– – – – – – – – – – – – – – – – – – – – – – – – – C – E113D 1 0 1
A4/Asian – – – – – – – – – – – G – – – – – – – – – – – – – – – D25E 117 24 141
– c – – – – – – – – – G – – – – – – – – – – – – – – – D25E 0 1 1
– – C – – – – – – – – G – – – – – – – – – – – – – – – Q3P/D25E 1 0 1
– – – c – – – – – – – G – – – – – – – – – – – – – – – D25E 11 2 13
– – – c – – – – – – – G – C – – – – – – – – – – – – – D25E/E29Q 1 0 1
– – – – – – – – G – – G – – – – – – – – – – – – G – – T22S/D25E/L83V 2 0 2
– – – – – – – – – – – G – – c – – – – – – – – – – – – D25E 1 0 1
– – – – – – – – – – – G – – – – g – – – – – – – – – – D25E 1 0 1
– – – – – – – – – – – G – – – – – A – – – – – – – – – D25E/R55L 1 0 1
– – – – – – – – – – – G – – – – – – – – – – – T – – – D25E/H78Y 1 0 1
– – – – – – – – – – – G – – – – – – – – – – – – – – G D25E/S138C 0 1 1
D – – – – C – T – – – – – – – – – – – – a – – – T – – – R10T/Q14H/H78Y 1 0 1
a Variant classiﬁcation based on the E6 sequences.
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Table 3
Studies included in meta-analysis.
First author,
year
Region Gene
tested
Control (normal cytol-
ogy/low grade lesions)
Case (ICC)
A1–3 A4 A1–3 A4
Present study China E6 57 28 161 136
Sun, 2013 China E6, LCR 113 24 19 31
D. Hang et al. / Virology 488 (2016) 156–161158cervical cancer among Chinese and Japanese women (Matsumoto
et al., 2000; Sun et al., 2013), but not in Hongkong and Korean
populations (Chan et al., 2002; Kang et al., 2005).
To clarify the association between HPV16 A4/Asian variants and
cervical cancer risk, we conducted this case-control study with
298 cervical cancer patients and 85 healthy controls (all HPV16-
positive) from Chinese women. In addition, we performed a meta-
analysis to evaluate associations in East Asian populations.Ding, 2010 China E6, E7 10 29 6 42
Matsumoto,
2000
Japan E6 16 4 22 19
Kang, 2005 Korea E6 0 8 3 23
Cornet, 2013 Korea E6 2 2 7 35
Cornet, 2013 Thailand E6 3 18 30 146
Chopjitt, 2009 Thailand E6 7 2 6 17
Total 208 115 254 449Results
A total of 298 cases and 85 controls are included in subsequent
analyses (after exclusion of two cases co-infected with more than
one HPV16 variant). In cases, 289 (97.0%) were diagnosed with
squamous cell carcinoma, 7 (2.3%) with adenocarcinoma, and 2
(0.7%) with adenosquamous carcinoma. The mean ages of cases
and controls were similar (49.278.5 years for cases and
48.4711.2 years for controls, P¼0.478).
HPV-16 E6 polymorphisms and variants
The most predominant variant sublineages among Chinese
women infected with HPV16 were A1–3 (56.9%, 218/383), followed
by A4/Asian (42.8%, 164/383) and D (0.3%, 1/383) (Table 1). Of 30
nucleotide polymorphisms identiﬁed in E6, 23 (76.7%) were non-
synonymous, including T178G (42.8%, 164/383), T350G (4.2%, 16/
383), and G176A (3.7%, 14/383) as the three most frequent
changes.
Association of HPV16 variants with cervical cancer risk
A4/Asian variants were signiﬁcantly associated with a higher
risk of cervical cancer compared with A1–3 (Odds ratio (OR)¼1.72,
95% conﬁdence interval (CI)¼1.04–2.85; P¼0.036) (Table 2). The
association did not change materially after adjusting for age.
A1–3 variants were further stratiﬁed into 350T and 350G
(based on polymorphism at position 350, regardless of sequences
at other positions), and no signiﬁcant difference in the distribution
of these variants was observed between cases and controls
(OR¼0.62, 95% CI¼0.20–1.92; P¼0.404).
Meta-analysis
A total of six studies evaluating the risk of HPV16 A4/Asian
variants for invasive cervical cancer (ICC) in East Asia were inclu-
ded (Table 3). Cervical samples were derived fromwomen in China
(Ding et al., 2010; Sun et al., 2013), Japan (Matsumoto et al., 2000),
Korea (Cornet et al., 2013; Kang et al., 2005), and Thailand
(Chopjitt et al., 2009; Cornet et al., 2013). All studies used PCR plus
sequencing to detect viral variants and HPV16 E6 gene was
sequenced in each study, A4/Asian variants being predominantly
deﬁned by the presence of the polymorphism T178G.Table 2
Association between HPV16 variants and cervical cancer.
Varianta Case (N¼298) Control
(N¼85)
OR (95% CI) OR (95% CI)
A1–3 161 (54.0) 57 (67.1) Reference
350T 152 (51.0) 52 (61.2) Reference
350G 9 (3.0) 5 (5.9) 0.62 (0.20, 1.92)
A4/Asian 136 (45.6) 28 (32.9) 1.72 (1.04, 2.85)
D 1 (0.3) 0 (0.0)
OR, odds ratio; CI, conﬁdence interval.
a Variant classiﬁcation based on the E6 sequences.Together with our present study, a total of 703 womenwith ICC
(HPV16-positive) and 323 with normal cytology or low-grade
lesions (HPV16-positive) were included in the meta-analysis.
Overall, A4/Asian variants were signiﬁcantly associated with ICC
compared to A1–3 variants (OR¼2.82, 95% CI¼1.44–5.52;
P¼0.003) (Fig. 1). Sensitivity testing was conducted by omitting
each study in turn to evaluate its inﬂuence on the meta-analysis.
No single study altered the pooled ORs substantially, indicating
that the results of meta-analysis were robust (Fig. 2). No obvious
asymmetry of the funnel plots was observed for included studies
(Fig. 3) and the Egger's test was nonsigniﬁcant (P¼0.896), thus
suggesting that no signiﬁcant publication bias existed.
ICC, invasive cervical cancer.Discussion
Although the burden of cervical cancer in China is substantial,
there are limited data on the epidemiology of HPV variants among
Chinese population. In this study, we investigated the sequence
polymorphisms of HPV16 E6 oncogene and evaluated their onco-
genic implications among Chinese women. We found that A1–3
and A4/Asian were the most common HPV16 variant sub-lineages
in China. Compared with A1–3, A4/Asian variants were sig-
niﬁcantly associated with elevated risk of cervical cancer. A sys-
tematic meta-analysis further supported that A4/Asian variants
confer higher carcinogenicity among East Asian women.
It is well known that HPV16 variants display differential geo-
graphic distributions and our study conﬁrmed that A lineages
account for a majority of HPV16 isolates in Asian populations
(Cornet et al., 2013; Yamada et al., 1997). However, previous stu-
dies reached inconsistent conclusions on whether A4/Asian var-
iants represent a higher risk for cervical cancer (Kang et al., 2005;
Matsumoto et al., 2000; Sun et al., 2013). In the present study, that
was by far the largest to date, we found a signiﬁcant association of
A4/Asian variants with cervical cancer in China, consistent with
previous studies in Japan and Thailand (Chopjitt et al., 2009;
Matsumoto et al., 2000). Given that HPV16-positive controls need
to be derived from large population-based screening programs,
relatively small number of controls is the inherent problem in
many studies. Thus, we pooled data from six studies together with
ours, and conﬁrmed that HPV16 A4/Asian variants were more
oncogenic than A1–3 variants. Although signiﬁcant heterogeneity
between studies was observed, there was no evidence of pub-
lication bias, and the association was statistically robust in sensi-
tivity testing.
We also studied the most common polymorphism within A1–3
variants, namely 350T/G, but found no signiﬁcant association with
cervical cancer in our Chinese population. However, 350G was
rare, conﬁrming observations from other East Asian studies (Chang
Fig. 1. Forest plots with odds ratios (ORs) of cervical cancer for HPV16 A4/Asian variants.
Fig. 2. Sensitivity analysis of the pooled odds ratios (ORs) of cervical cancer for HPV16 A4/Asian variants.
D. Hang et al. / Virology 488 (2016) 156–161 159et al., 2013; Kang et al., 2005), in comparison to those from Europe
and the Americas where it is more frequent (Cornet et al., 2013;
Yamada et al., 1997). The risk implications of this common poly-
morphism have been widely studied, with discrepant results
(Chan et al., 2002; Grodzki et al., 2006; Zehbe et al., 2001, 1998),
leading some authors to suggest that the carcinogenicity of 350T
vs 350G might be population-dependent (Cornet et al., 2013;
Zehbe et al., 2001). Host genetic factors, which differ by popula-
tion, might have a role in the association between a particular
HPV16 variant and cervical cancer development. However, differ-
ences by population might be simply explained by residual genetic
heterogeneity within HPV16 genomes classiﬁed solely upon posi-
tion 350, which, although highly polymorphic, does not seem to
robustly deﬁne phylogenetic sublineages (Chen et al., 2005).
Unfortunately, we were not able to compare the phylogeneticallymeaningful sublineages of A1, A2 and A3, due to lack of resolution
based solely on E6.
The association of HPV16 E6 variants with cervical cancer risk
may be explained by improved viral ﬁtness (i.e. ability to evade
host immune system and establish a persistent infection) and/or
enhanced carcinogenicity. Functional studies suggested that
T350G may have biological advantages over the reference to
abrogate the serum/calcium-dependent differentiation of primary
human foreskin keratinocytes (PHFKs) (Asadurian et al., 2007), to
promote cellular immortalization and down-regulate E-cadherin
(Togtema et al., 2015), as well as to enhance E6-mediated MAPK
signaling and cooperative transformation with deregulated Notch1
pathway (Chakrabarti et al., 2004; Sichero et al., 2012). However,
there are relatively less functional data on T178G, the diagnostic E6
polymorphism for A4/Asian variants. It was reported that T178G
induced degradation of tumor suppressor p53 at a similar level to
Fig. 3. Funnel plots of included studies on the association of HPV16 A4/Asian
variants with cervical cancer risk.
D. Hang et al. / Virology 488 (2016) 156–161160the reference E6 (Hang et al., 2014; Yi et al., 2013), but a micro-
array experiment identiﬁed 14 other genes affected differentially
by this variation (Jang et al., 2011). Thus, more functional studies of
T178G and other linked polymorphisms throughout the HPV16
genome of A4/Asian variants are necessary to explore the biolo-
gical evidence of increased carcinogenicity.
In summary, our study provides evidence that HPV16 A4/Asian
variants may predict higher cervical cancer risk among Chinese
women. These ﬁndings provide the basis for HPV16 genome wide
studies to better determine the exact genetic determinants of
differences in carcinogenicity of HPV16 variants.Materials and methods
Study population
Cervical cancer cases were consecutively recruited from Cancer
Institute and Hospital, Chinese Academy of Medical Sciences in
Beijing, China, since January 2010 to July 2012. All cases were
newly diagnosed and histologically conﬁrmed invasive cancer.
Control subjects were from the population who participated in a
hospital-based screening program for cervical cancer in Beijing
conducted by Department of Cancer Prevention, Cancer Institute
and Hospital, Chinese Academy of Medical Sciences, since January
2010–July 2012. Controls had no abnormal intraepithelial lesions
identiﬁed by liquid-based cytology (LBC) and were frequency-
matched to the cases by age (75 years). Written informed consent
was obtained from each subject. This study was approved by the
ethics committees of Cancer Institute and Hospital, Chinese
Academy of Medical Sciences and Nanjing Medical University.
HPV genotyping
The β-actin gene (forward primer, 50-GAAATCGTGCGTGA-
CATTAA-30; reverse primer 50-AAGGAAGGCTGGAAGAGTG-30) was
ampliﬁed by polymerase chain reaction (PCR) to conﬁrm the
quality of DNA extracted from exfoliated cervical cells. All β-actin
positive specimens were tested for HPV DNA by using a HPV
GenoArray Test Kit (HybriBio Ltd., Beijing, China), which could
identify 21 HPV types simultaneously (13 high-risk types: HPV16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; two intermediate-
risk types 53 and 66; and six low-risk HPV types: HPV6, 11, 42, 43,
44, and 81). In total, 300 of 607 cancer cases and 85 controls from
the cohort of 5066 participants were HPV16-positive and included
in this study.Variant identiﬁcation
HPV16-positive samples were analyzed for E6 polymorphisms
by PCR ampliﬁcation of 545-bp product followed by sequencing.
Brieﬂy, type-speciﬁc primers applied were ﬂanking outside of the
coding region of HPV16 E6 (nucleotides 21-565): forward primer
50-AAACTAAGGGCGTAACCGAA and reverse primer 50-GCATGAT-
TACAGCTGGGTTTCTC. The PCR mixture contained 50 ng template
DNA, 0.2 μM each primer, 0.2 mM deoxynucleoside triphosphate,
1PCR buffer containing 1.5 mM MgCl2, and 0.8 U HotStarTaq
DNA polymerase (Qiagen, Germany). After a 15 min enzyme acti-
vation at 95 °C, 35 cycles of ampliﬁcation (94 °C for 40 s, 58 °C for
50 s, and 72 °C for 40 s) and a ﬁnal extension at 72 °C for 10 min
were carried out. For quality control, a negative control reaction
without DNA template and a positive control reaction with HPV16
plasmid DNA were included in each PCR test. Double-stranded
sequencing of the ampliﬁed product was performed using the
same primers as in PCR. E6 polymorphisms were identiﬁed by
comparison to the reference HPV16 sequence (GenBank: K02718),
and intratype variants were classiﬁed based on E6 sequences as
previously described (Cornet et al., 2012; Huertas-Salgado et al.,
2011).
Meta-analysis
We searched all epidemiological studies on the association
between HPV16 variants and cervical cancer in East Asian popu-
lations. Eligible studies, published in English, up to June 2015,
were identiﬁed by using the search terms “Human papillomavirus
16, Asian variant, T178G, cervical cancer” in Pubmed. Additional
relevant references cited in retrieved articles were also evaluated.
If data were published more than once, only the publication with
the largest sample size was included. The raw data were abstrac-
ted independently by two reviewers. If different results were
generated, they were discussed until a consensus was reached.
Odds ratios (ORs) and relevant 95% conﬁdence intervals (CIs) were
calculated in logistic regression models. The Cochran's Q-test and
I2 statistic were performed to assess the heterogeneity between
studies (Higgins and Thompson, 2002). If there was signiﬁcant
heterogeneity (Po0.05 or I2450%), a random-effects model was
applied instead of a ﬁxed-effect model to pool the data of included
studies. Publication bias was examined by funnel plots and the
Egger test (Sterne and Egger, 2001).
Statistical analyses
Differences in demographic characteristics between cases and
controls were evaluated by using the Student's t-test and the χ2-
test for continuous and categorical variables, respectively. The
association between HPV16 variants and cervical cancer risk was
estimated by computing the ORs and 95% CIs in logistic regression
models. All P values presented were two-sided and were assumed
signiﬁcant as Po0.05. Statistical analyses were conducted using
Stata version 11.0 (Stata Corporation, College Station, TX, USA).Acknowledgments
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